Fig. 1
From: GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma
Validation GLRX3 expression in pancreatic cancer cell lines: A-B GLRX3 expression in pancreatic cancer cell lines. A GLRX3 mRNA was expressed in various pancreatic cancer cell lines. B GLRX3 protein was expressed in various pancreatic cancer cell lines. C Semi-quantitative RT-PCR of GLRX3 levels in adherent cells and spheres. GLRX3 mRNA was overexpressed in spheres compared to adherent HPAC cells; D Semi-quantitative RT-PCR of GLRX3 levels in CD24+/CD44+/ESA+ cells and CD24−/CD44−/ESA- cells. HPAC cells were fluorescence stained with CD24-PE, CD44-APC, and ESA-FITC, and then isolated by FACS. GLRX3 mRNA was increased in CD24+/CD44+/ESA+ cells than in the CD24−/CD44−/ESA- cells; E Confirmation of GLRX3 in western blot analysis. GLRX3 showed increased expression in the supernatant of spheres compared to that of adherent cells. Between total lysate of spheres and adherent cells, GLRX3 showed similar expressions in HPAC and increased expression in spheres of the Capan-1